Almost a third of people report at least one ongoing symptom between 6 and 12 months after their coronavirus infection, according to a survey of 152,000 people in Denmark.
On the day the public and members of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee were going to get a look at Pfizer and BioNTech’s COVID-19 vaccine data for children under 5 years old, the companies pulled the Emergency Use Authorization (EUA) submission.
For both patients and their healthcare providers (HCPs), the requirement that prior authorizations (PAs) be obtained from health insurers for many branded and specialty medications continues to act as a significant roadblock, according to David Fidler, senior director product innovation at ConnectiveRx.
SubjectWell – the largest risk-free clinical trials marketplace – released statistics on patients’ attitudes toward clinical research, specifically those with liver diseases.
